Metabolic Adaptations to Pregnancy in Healthy and Gestational Diabetic Pregnancies: The Pancreas - Placenta Axis.

Abstract:

:Normal pregnancy is associated with increased insulin resistance as a metabolic adaptation to the nutritional demands of the placenta and fetus, and this is amplified in obese mothers. Insulin resistance is normally compensated for by an adaptive increase in pancreatic β-cell mass together with enhanced glucose-stimulated insulin release. Placentally-derived hormones and growth factors are central to the altered pancreatic morphology and function. A failure of β-cells to undergo adaptive change after the first trimester has been linked with gestational diabetes. In the pregnant mouse, an increase in β-cell replication contributes to a 2-3-fold increase in mass peaking in late gestation, depending on the proliferation of existing β-cells, the differentiation of resident progenitor β-cells, or islet cell transdifferentiation. Using mouse models and human studies placenta- and islet of Langerhans-derived molecules have been identified that are likely to contribute to the metabolic adaptations to pregnancy and whose physiology is altered in the obese, glucose-intolerant mother. Maternal obesity during pregnancy can create a pro-inflammatory environment that can disrupt the response of the β-cells to the endocrine signals of pregnancy and limit the adaptive changes in β-cell mass and function, resulting in an increased risk of gestational diabetes.

journal_name

Curr Vasc Pharmacol

authors

Szlapinski SK,Hill DJ

doi

10.2174/1570161118666200320111209

subject

Has Abstract

pub_date

2021-01-01 00:00:00

pages

141-153

issue

2

eissn

1570-1611

issn

1875-6212

pii

CVP-EPUB-105412

journal_volume

19

pub_type

杂志文章
  • Effects of kallistatin on oxidative stress and inflammation on renal ischemia-reperfusion injury in mice.

    abstract:BACKGROUND:Kallistatin (KS) is a serine proteinase. The result of KS on 'Renal Ischemia- Reperfusion Injury' (IRI) has not clearly been researched. In this study, investigative research has been conducted to draw results on the administration of human KS on kidney response conducted within a mouse model of IRI. MATERI...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章

    doi:10.2174/1570161113666150204142716

    authors: Zhou S,Sun Y,Zhuang Y,Zhao W,Chen Y,Jiang B,Guo C,Zhang Z,Peng H,Chen Y

    更新日期:2015-01-01 00:00:00

  • Current and Potential Future Pharmacological Approaches for Non- Alcoholic Fatty Liver Disease.

    abstract:BACKGROUND:Non-alcoholic fatty liver disease (NAFLD) affects a large proportion of the general population. The disease ranges from simple steatosis, to non-alcoholic steatohepatitis (NASH), cirrhosis and even hepatocellular carcinoma. Several drugs are used in daily clinical practice to manage the disease. However, dat...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/1570161115666170621083744

    authors: Imprialos K,Stavropoulos K,Bouloukou S,Kerpiniotis G,Karagiannis A,Doumas M

    更新日期:2018-01-01 00:00:00

  • Involvement of coagulation and hemostasis in inflammatory bowel diseases.

    abstract::Inflammatory bowel diseases (IBD), Crohn's disease and ulcerative colitis (UC) are idiopathic, intestinal and systemic inflammatory disorders which are immunologically mediated with the activation of plasma proteolytic cascades. The activation of coagulation in IBD is related to the activity and colonic extension of t...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/157016112801784495

    authors: Stadnicki A

    更新日期:2012-09-01 00:00:00

  • Effects of insulin on the vasculature.

    abstract::Revascularization procedures used for the treatment of cardiovascular disease can be associated with restenosis, although drug-coated stents have greatly reduced this complication. Both type 2 diabetes (T2DM) and metabolic syndrome (MetS) are associated with a high risk for atherosclerosis and restenosis. Insulin resi...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/157016111795495558

    authors: Breen DM,Giacca A

    更新日期:2011-05-01 00:00:00

  • Role of pharmacotherapy in cardiac ion channelopathies.

    abstract::In the last decade there have been considerable advances in the understanding of the pathophysiology of malignant ventricular tachyarrhythmias (VA) and Sudden Cardiac Death (SCD). Over 80% of SCD occurs in patients with organic heart disease. However, approximately 10-15% of SCD occurs in the presence of structurally ...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/157016109788340794

    authors: El-Sherif N,Pedalino R,Himel H 4th

    更新日期:2009-07-01 00:00:00

  • Pleiotropic effects of the rho-kinase inhibitor fasudil after subarachnoid hemorrhage: a review of preclinical and clinical studies.

    abstract::There is growing evidence that Rho-kinase contributes to cardiovascular disease, which has made Rho-kinase a target for the treatment of human diseases. To date, the only Rho-kinase inhibitor employed clinically in humans is fasudil, which has been used for the prevention of cerebral vasospasm and subsequent ischemic ...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/1570161112666140613115813

    authors: Satoh S,Ikegaki I,Kawasaki K,Asano T,Shibuya M

    更新日期:2014-01-01 00:00:00

  • Perivascular adipose tissue, inflammation and vascular dysfunction in obesity.

    abstract::Adipocytes are no longer considered just as cells related to storage of energy and thermoregulation. Now we know that they release a huge number of paracrine and endocrine biologically active molecules. This is also the case for perivascular adipose tissue (PVAT) that surrounds almost all blood vessels in the organism...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/1570161112666140423220628

    authors: Van de Voorde J,Boydens C,Pauwels B,Decaluwé K

    更新日期:2014-05-01 00:00:00

  • Impact of immunosuppressive drugs on the development of cardiac allograft vasculopathy.

    abstract::Immunosuppressive drugs (ISDs) have a major impact on the development and progression of cardiac allograft vasculopathy (CAV), the main cause of cardiac allograft loss and a leading cause of death beyond the 1st post-transplant year. The influence of ISDs on the development and progression of CAV is complex. In spite ...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/157016110792006923

    authors: Dandel M,Hetzer R

    更新日期:2010-09-01 00:00:00

  • Dynamic Changes in Phenotypic Groups in Patients with Stable Angina Pectoris after Treatment with Xinxuekang Capsule: A Randomized Controlled Trial.

    abstract:OBJECTIVE:To reveal the cutoff point and influencing factors in the dynamic change in phenotypic group in patients with stable angina pectoris (SAP) after Xinxuekang capsule treatment. METHODS:Five hundred and seventy-six SAP patients were randomly assigned to receive Xinxuekang (XXK) capsules or Compound Danshen (CDS...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.2174/1570161112666141014151858

    authors: Wang LY,Tang JY,Liu J,Lu W,Yu YN,Chen BW,Wu HL,Su LY,Jing ZW,Hu SY,Liu XL,Yang XY,Li GX,Dong B,Wang DH,Xue J,Wang XF,Li ZM,Liu SR,Liu SS,Chen QG,Zhang L,Wang Z,Shen CT,Wang YY

    更新日期:2015-01-01 00:00:00

  • Visfatin/PBEF and atherosclerosis-related diseases.

    abstract::Visfatin is highly expressed in adipose tissue (mainly by the stromal cells), but it is also ubiquitously present in most tissues. Visfatin, which plays a role in nicotinamide adenine dinucleotide (NAD) biosynthesis, has been implicated in inflammatory states. Controversial results exist about the expression, circulat...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/157016110790226679

    authors: Filippatos TD,Randeva HS,Derdemezis CS,Elisaf MS,Mikhailidis DP

    更新日期:2010-01-01 00:00:00

  • Regulation of blood flow by prostaglandins.

    abstract::Prostaglandins (PGs) belong to the family of prostanoids together with thromboxanes and are produced mainly from arachadonic acid by the enzyme cyclooxygenase. PGs are known to stimulate platelet aggregation, mediate inflammation and edema, play a role in bone metabolism and in biological adaptation of connective tiss...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/1570161043476410

    authors: Boushel R,Langberg H,Risum N,Kjaer M

    更新日期:2004-04-01 00:00:00

  • Statins: Are they really all the same?

    abstract:: ...

    journal_title:Current vascular pharmacology

    pub_type: 社论

    doi:10.2174/1570161116666180713120217

    authors: Cortese F

    更新日期:2019-01-01 00:00:00

  • Biochemical strategies to anticoagulation: a comparative overview.

    abstract::Hypercoagulability is widely associated with sepsis, inflammation, diabetes, cancers, aging, and many pathological conditions, resulting in life-threatening disseminated intravascular coagulation (DIC), venous thrombosis, thromboembolism, cardiovascular complications, or even deadly multiple organ failure. Relieving c...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/1570161043385673

    authors: Chu AJ

    更新日期:2004-07-01 00:00:00

  • The etiology of hypertension in the metabolic syndrome part two: the gene-environment interaction.

    abstract::The pathogenesis of obesity, insulin resistance and hypertension begins with an interaction between genetic factors and environmental factors. The search for the underlying genetic basis of these conditions has yielded disappointing results. It is possible that the importance of environmental influences has been under...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/157016106778521661

    authors: Sharma V,McNeill JH

    更新日期:2006-10-01 00:00:00

  • Recommendations for severe hypertriglyceridemia treatment, are there new strategies?

    abstract::This review considers drug combinations and newer treatment strategies for patients with severe hypertriglyceridemia. Hypertriglyceridemia is associated with an atherogenic metabolic profile and in most studies with increased cardiovascular disease risk. Patients with severe hypertriglyceridemia also have increased in...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/15701611113119990133

    authors: Filippatos TD,Elisaf MS

    更新日期:2014-01-01 00:00:00

  • Acute coronary syndromes in patients with chronic kidney disease.

    abstract::Chronic kidney disease (CKD) is associated with high cardiovascular morbidity and mortality. The available data suggest that efforts to reduce mortality in the CKD population should be focused on treatment and prevention of, among others, coronary artery disease and congestive heart failure. Accelerated atherosclerosi...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/1570161111311050013

    authors: Franczyk-Skóra B,Gluba A,Banach M,Rozentryt P,Poloński L,Rysz J

    更新日期:2013-09-01 00:00:00

  • Cardiovascular toxicity from the perspective of oxidative stress, electron transfer, and prevention by antioxidants.

    abstract::This review demonstrates that oxidative stress, reactive oxygen species, and electron transfer can serve as unifying mechanistic themes for large numbers of cardiovascular toxins, both endogenous and exogenous. Lipid peroxidation is a prevalent insult. Common among the various conditions are atherosclerosis and arrhyt...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/1570161053586912

    authors: Kovacic P,Thurn LA

    更新日期:2005-04-01 00:00:00

  • The Management of Dyslipidaemia in Patients with Type 2 Diabetes Mellitus Receiving Lipid-Lowering Drugs: A Sub-Analysis of the CEPHEUS Findings.

    abstract:BACKGROUND:Dyslipidaemia is a risk factor for macrovascular complications in patients with type 2 diabetes mellitus (T2DM). Our aim was to assess the use of lipid lowering drugs (LLDs) in patients with T2DM and co-existing dyslipidaemia. METHOD:A multicentre, non-interventional survey conducted in 6 Middle Eastern cou...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,多中心研究

    doi:10.2174/1570161115666170705153815

    authors: Shehab A,Al-Rasadi K,Arafah M,Al-Hinai AT,Al Mahmeed W,Bhagavathula AS,Al Tamimi O,Al Herz S,Al Anazi F,Al Nemer K,Metwally O,Alkhadra A,Fakhry M,Elghetany H,Medani AR,Yusufali AH,Al Jassim O,Al Hallaq O,Baslaib FOAS

    更新日期:2018-01-01 00:00:00

  • Renalase is removed by kidneys and during dialysis - excess related to CKD complications?

    abstract:BACKGROUND:The most common complications of chronic kidney disease (CKD) are hypertension and cardiovascular (CV) disorders. Renalase is produced and released by the kidney and also cardiomyocytes. Renalase deficiency was claimed to be responsible for hypertension and CV complication in CKD. There are contradictory dat...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章

    doi:10.2174/1570161113666141217141805

    authors: Malyszko J,Koc-Zorawska E,Zorawski M,Kozminski P,Zbroch E,Rysz J,Banach M,Malyszko JS

    更新日期:2015-01-01 00:00:00

  • Endothelin-1 and nitric oxide in the pathogenesis of urinary tract disorders secondary to bladder outlet obstruction.

    abstract::Bladder outlet obstruction (BOO) is a common disorder that is associated with urinary tract symptoms. Nitric oxide (NO), synthesized by NO synthase (NOS) is a potent vasodilator that is present throughout the urinary tract and the corpus cavernosum. Endothelin-1 (ET-1) conversely is a potent vasoconstrictor peptide th...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/1570161033386600

    authors: Khan MA,Thompson CS,Dashwood MR,Mumtaz FH,Morgan RJ,Mikhailidis DP

    更新日期:2003-03-01 00:00:00

  • Antenatal hypoxia and pulmonary vascular function and remodeling.

    abstract::This review provides evidence that antenatal hypoxia, which represents a significant and worldwide problem, causes prenatal programming of the lung. A general overview of lung development is provided along with some background regarding transcriptional and signaling systems of the lung. The review illustrates that ant...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/1570161111311050006

    authors: Papamatheakis DG,Blood AB,Kim JH,Wilson SM

    更新日期:2013-09-01 00:00:00

  • Mineralocorticoid Antagonists in ESRD: An Overview of Clinical Trial Evidence.

    abstract:BACKGROUND:Add-on therapy with the Mineralocorticoid-Receptor-Antagonists (MRAs) spironolactone and eplerenone was shown to enhance the cardioprotective action of angiotensinconverting- enzyme-inhibitors (ACEIs), angiotensin-receptor-blockers (ARBs) and/or β-blockers in nondialysis patients with congestive heart failur...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/1570161115666170201113817

    authors: Georgianos PI,Vaios V,Eleftheriadis T,Zebekakis P,Liakopoulos V

    更新日期:2017-01-01 00:00:00

  • Treatment of Diabetic Cardiovascular Autonomic, Peripheral and Painful Neuropathy. Focus on the Treatment of Cardiovascular Autonomic Neuropathy with ACE Inhibitors.

    abstract::Neuropathies of the peripheral and autonomic nervous systems affect up to half of all people with diabetes mellitus, and are major risk factors for foot ulceration, amputation and cardiovascular dysfunction. Peripheral neuropathies manifest with either painful or painless symptoms, but many patients experience both. O...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/1570161117666190521101342

    authors: Didangelos T,Veves A

    更新日期:2020-01-01 00:00:00

  • Endothelial dysfunction in cardiac allograft vasculopathy: potential pharmacological interventions.

    abstract::Nowadays long-term outcome of heart transplantation is limited by a peculiar type of coronary atherosclerosis, known as cardiac allograft vasculopathy (CAV). Although the exact pathogenesis of CAV remains unclear, emerging evidence indicates that the endothelium plays a significant role in the onset and progression of...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/157016110790886992

    authors: Osto E,Tona F,De Bon E,Iliceto S,Cella G

    更新日期:2010-03-01 00:00:00

  • Statins and cardiovascular events in patients with end-stage renal disease on hemodialysis. The AURORA results suggest the need for earlier intervention.

    abstract::The recently published Assessment of Survival and Cardiovascular Events (AURORA) trial showed that rosuvastatin (10 mg/d) compared with placebo did not result in a significant reduction in vascular events despite a 43% fall in low density lipoprotein cholesterol (LDL-C) levels in patients with end-stage renal disease ...

    journal_title:Current vascular pharmacology

    pub_type: 社论,评审

    doi:10.2174/157016109788340712

    authors: Athyros VG,Tziomalos K,Karagiannis A,Mikhailidis DP

    更新日期:2009-07-01 00:00:00

  • Editorial: aliskiren/amlodipine single-pill combinations: more evidence in favour of combination formulations for the treatment of hypertension.

    abstract::In this issue of Curr Vasc Pharmacol, Pfeiffer et al. [1] and Glorioso et al. [2] report the efficacy and tolerability of aliskiren/amlodipine single-pill combinations (SPCs) in patients with inadequate blood pressure (BP) response to amlodipine or aliskiren monotherapy, respectively. ...

    journal_title:Current vascular pharmacology

    pub_type: 评论,社论

    doi:10.2174/157016112803520783

    authors: Katsiki N,Athyros VG,Mikhailidis DP,Karagiannis A

    更新日期:2012-11-01 00:00:00

  • Understanding the mechanism of platelet thrombus formation under blood flow conditions and the effect of new antiplatelet agents.

    abstract::Platelet aggregation induced by stirring of a platelet suspension after activation by the exogenous addition of stimulants, such as ADP, epinephrine and thrombin, has long been used as a platelet function test, and for the screening of antiplatelet agents. Since platelet aggregation has been demonstrated to be mediate...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/1570161043476456

    authors: Goto S

    更新日期:2004-01-01 00:00:00

  • Role of matrix metalloproteinases in animal models of ischemic stroke.

    abstract::Matrix metalloproteinases (MMP) comprise a family of at least 25 zinc-dependent endopeptidases that play a pivotal role in the physiopathology of the mammalian central nervous system. In the first phases after stroke, the dysregulation of MMPs has been described to increase acute neurovascular disruption and cerebral ...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/15701611113116660161

    authors: Lenglet S,Montecucco F,Mach F

    更新日期:2015-01-01 00:00:00

  • Use of BNP and CRP as biomarkers in assessing cardiovascular disease: diagnosis versus risk.

    abstract::Biomarkers are used in medicine to facilitate diagnosis, assess risk, direct therapy and determine efficacy of treatment. Sensitivity and specificity are essential in order for a biomarker to be useful. Brain natriuretic peptide (BNP) and C-reactive protein (CRP) are considered biomarkers of cardiovascular disease. Ho...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/157016107779317251

    authors: Miller VM,Redfield MM,McConnell JP

    更新日期:2007-01-01 00:00:00

  • What is the Role for Glycoprotein IIb/IIIa Inhibitor Use in the Catheterization Laboratory in the Current Era?

    abstract:BACKGROUND:In the era of dual antiplatelet therapy of aspirin and clopidogrel and systematic stent implantation, Glycoprotein IIb/IIIa Inhibitors (GPI), including abciximab, eptifibatide and tirofiban, proved beneficial in improving early outcome of Percutaneous Coronary Intervention (PCI), especially in higher risk cl...

    journal_title:Current vascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.2174/1570161116666180117102422

    authors: Rubboli A,Patti G

    更新日期:2018-01-01 00:00:00